Strong Intellectual Property With over 25 years of research and nearly 1,000 patents, CureVac demonstrates a robust IP portfolio in mRNA technology, presenting opportunities to collaborate on innovative vaccine and therapeutic development leveraging their core assets.

Emerging Oncology Focus CureVac is advancing personalized cancer vaccines and treatments using mRNA, indicating potential for partnerships with biotech and pharma companies seeking cutting-edge solutions in oncology and regenerative medicine.

Strategic Funding and Growth Having secured €416.1 million in cash and funding into 2028 plus ongoing clinical programs, CureVac presents a compelling partner for investors or collaborators interested in early-stage biotech with solid financial backing and promising product pipelines.

Regulatory Momentum Recent EMA approval for clinical trials and approval of COVID-19 vaccine-related agreements position CureVac to expand its portfolio, offering opportunities for joint ventures in vaccine development and regulatory consulting.

Global Expansion Potential Headquartered in Germany with operations in North America and Europe, CureVac’s international footprint opens avenues for cross-border collaborations, licensing deals, and market entry strategies across global healthcare markets.